•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Defective Drugs
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and time to contact you:

Date of birth (mm-dd-yyyy):

Name of drug:

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

DEFECTIVE DRUGS

AddThis Social Bookmark Button

Parker Waichman Alonso LLP is a leader in defective drug litigation. We are currently evaluating cases involving defective drugs throughout the United States. To view more information involving a specific defective drug, please click on one of the links listed below. Please fill out the form at the right for a free case evaluation by a qualified attorney.

Defective Drugs

Defective Drugs NewsRSS Feed

Another Study Sees Avandia, Actos Fracture Risk

Jul 30, 2010 | Parker Waichman Alonso LLP
Another study has added to the growing body of evidence linking Avandia and Actos to an increased risk of fractures. This latest research, which...

FDA Says Cubicin May Cause Deadly Form of Pneumonia

Jul 29, 2010 | Parker Waichman Alonso LLP
The antibiotic Cubicin (daptomycin) has been associated with life-threatening eosinophilic pneumonia, the U.S. Food & Drug Administration (FDA)...

Glaxo Apologizes for Paid Journal Supplement

Jul 27, 2010 | Parker Waichman Alonso LLP
GlaxoSmithKline has apologized for failing to disclose its role in preparing content for a paid supplement to a medical journal last year. According...

FDA Refers Avandia Panel Conflict Question to HHS

Jul 27, 2010 | Parker Waichman Alonso LLP
Federal drug regulators have referred a potential conflict-of-interest problem on an Avandia advisory panel to the inspector general’s office...

Study Finds Some New Epilepsy Treatments May Up Suicide Risks

Jul 27, 2010 | Parker Waichman Alonso LLP
A recent study has found evidence that the newer epilepsy drugs Keppra, Topamax, and Sabril are associated with a higher risk of suicidal behavior...

Avandia Decision Coming in September, European Regulators Say

Jul 23, 2010 | Parker Waichman Alonso LLP
European regulators will decide by September if Avandia will be allowed to stay on the market there. The European Medicines Agency (EMEA) said...

Glaxo Paxil Birth Defects Settlements Total $1 Billion

Jul 22, 2010 | Parker Waichman Alonso LLP
GlaxoSmithKline (GSK) has agreed to pay in excess of $1 billion to settle hundreds of lawsuits over claims of birth defects linked to Paxil, said...

FDA Details Multiple Violations at Another Johnson & Johnson Plant

Jul 22, 2010 | Parker Waichman Alonso LLP
Federal inspectors found multiple violations at a Johnson & Johnson facility near Lancaster, PA that makes over-the-counter products like...

Tainted Heparin Never Investigated by Chinese Authorities

Jul 22, 2010 | Parker Waichman Alonso LLP
A congressional probe has found that Chinese authorities never bothered to investigate tainted heparin ingredients manufactured in that country, even...

Johnson & Johnson Gets Federal Subpoena Over Recalls

Jul 21, 2010 | Parker Waichman Alonso LLP
A federal grand jury has subpoenaed Johnson & Johnson as part of its investigation into its recent recall of over-the-counter medications....

FDA Halts Avandia Study Enrollment

Jul 21, 2010 | Parker Waichman Alonso LLP
US health regulators have ordered GlaxoSmithKline to stop recruiting patients for an Avandia trail. The trial, called TIDE (Thiazolidinedione...

FDA Advisor Who Voted in Favor of Avandia Had Ties to Glaxo

Jul 20, 2010 | Parker Waichman Alonso LLP
One of the members of a government advisory panel who voted to back Avandia last week was on GlaxoSmithKline’s payroll. According to The Wall...